-
公开(公告)号：US11926619B2
公开(公告)日：2024-03-12
申请号：US17045952
申请日：2019-04-08
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Gregg F. Keaney , John Wang , Baudouin Gerard , Kenzo Arai , Xiang Liu , Guo Zhu Zheng , Kazunobu Kira , Lisa A. Marcaurelle , Marta Nevalainen , Ming-Hong Hao , Morgan Welzel O'Shea , Parcharee Tivitmahaisoon , Sudeep Prajapati , Tuoping Luo , Nicholas C. Gearhart , Jason T. Lowe , Yoshihiko Kotake , Satoshi Nagao , Regina Mikie Kanada Sonobe , Masayuki Miyano , Norio Murai , Andrew Cook , Shelby Ellery , Atsushi Endo , James Palacino , Dominic Reynolds
IPC: C07D407/12 , A61K31/365 , A61K31/4427 , A61K31/497 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D407/06 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
CPC classification number: C07D407/06 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
-
公开(公告)号：US11498916B2
公开(公告)日：2022-11-15
申请号：US16722838
申请日：2019-12-20
Applicant: Eisai R&D Management Co., Ltd.
Inventor： George Moniz , Kristen Sanders , Arani Chanda , Kenshi Yoshida , Ming-Hong Hao , Dominic Reynolds , Sudeep Prajapati , Anand Selvaraj , Takashi Satoh , John Wang
IPC: C07D403/12 , C07D239/48 , A61K31/505
Abstract: A number of crystalline forms of N-(2-((6-(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-methylureido)pyrimidin-4-yl)amino)-5-(4-ethylpiperazin-1-y1)phenyl)acrylamide are provided. These include a crystalline free base form, a crystalline monohydrochloride salt form, a crystalline dihydrochloride salt form, and a crystalline ethanesulfonate salt form. Methods of making and using crystalline compounds are also provided.
-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US11352348B2
公开(公告)日：2022-06-07
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61P35/00 , A61K47/68 , A61K47/60 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US10912774B2
公开(公告)日：2021-02-09
申请号：US16717080
申请日：2019-12-17
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Dominic Reynolds , Ming-Hong Hao , John Wang , Sudeep Prajapati , Takashi Satoh , Anand Selvaraj
IPC: A61K31/505 , A61K31/506 , A61K31/5377
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
-
Patent Agency Ranking
公开(公告)号：US20200255415A1
公开(公告)日：2020-08-13
申请号：US16349479
申请日：2017-11-22
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Mark Bock , Ming-Hong Hao , Manav Korpal , Vijay Kumar Nyavanandi , Xiaoling Puyang , Susanta Samajdar , Peter Gerard Smith , John Wang , Guo Zhu Zheng , Ping Zhu , Lorna Helen Mitchell , Nicholas Larsen , Nathalie Rioux , Sudeep Prajapati , Dominic Reynolds , Morgan O'Shea , Thiwanka Samarakoon
IPC: C07D413/14 , A61P35/00 , C07D231/56 , C07D401/10 , C07D401/14 , C07D401/12 , C07D413/12 , C07D403/10
Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：US09730931B2
公开(公告)日：2017-08-15
申请号：US15221018
申请日：2016-07-27
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Dominic Reynolds , Ming-Hong Hao , John Wang , Sudeep Prajapati , Takashi Satoh , Anand Selvaraj
IPC: A61K31/505 , C07D239/48 , C07D405/12 , C07D413/12 , A61K31/506 , C07C53/18 , C07D401/12 , C07D403/12 , A61K31/5377
CPC classification number: A61K31/505 , A61K31/506 , A61K31/5377 , C07C53/18 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
-
公开(公告)号：US09434697B2
公开(公告)日：2016-09-06
申请号：US15000659
申请日：2016-01-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Dominic Reynolds , Ming-Hong Hao , John Wang , Sudeep Prajapati , Takashi Satoh , Anand Selvaraj
IPC: A61K31/505 , C07D239/48 , C07D401/12 , C07C53/18 , C07D403/12 , C07D413/12 , A61K31/506
CPC classification number: A61K31/505 , A61K31/506 , A61K31/5377 , C07C53/18 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。
-
公开(公告)号：US20160130237A1
公开(公告)日：2016-05-12
申请号：US15000659
申请日：2016-01-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Dominic Reynolds , Ming-Hong Hao , John Wang , Sudeep Prajapati , Takashi Satoh , Anand Selvaraj
IPC: C07D239/48 , C07D413/12 , C07D403/12 , C07D401/12 , C07C53/18
CPC classification number: A61K31/505 , A61K31/506 , A61K31/5377 , C07C53/18 , C07D239/48 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12
Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
Abstract translation: 本文提供了可用作FGFR4抑制剂的式I化合物，以及其用途的方法。
-
公开(公告)号：US12172986B2
公开(公告)日：2024-12-24
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.018 seconds)
